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ABSTRACT 
 
Estradiol and Genistein Alter Cellular Physiology of Non-malignant Colonocytes. 
(August 2011) 
Autumn Renee Billimek, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Clinton D. Allred 
  
 Many studies show that estradiol (E2) and consumption of soy and its primary 
phytoestrogen component genistein (GEN) can inhibit the formation of colon tumors. 
However, the effects of E2 and GEN at physiologically relevant levels in non-diseased 
colonocytes have yet to be investigated. We hypothesized that E2 and GEN could prove 
to be chemo-protective agents in the colon by moderately increasing apoptosis and 
decreasing proliferation in a healthy system. Thus, the presented studies focused on 
evaluating the effects of E2 and GEN in non-malignant colonocytes in vitro and in vivo 
to determine how the compounds influence the physiology of these cells. E2 (1 nM/L) 
and GEN treatments (1 and 10 µM/L) decreased cell growth, increased apoptosis, and 
increased p53 transcriptional activity in young adult mouse colonocytes, a non-
malignant cell line. To study further the effects of E2 and GEN in healthy colonic 
epithelia, we evaluated physiologic changes in colonic crypts in ovariectomized mice 
given an E2 pellet, 1,000 ppm GEN diet, or a phytoestrogen free diet. As seen in vitro, E2 
treated animals had significantly higher rates of apoptosis with GEN trending in the 
same fashion. These data demonstrate that E2 and GEN alter the physiology of non-
malignant colonocytes. 
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Collectively, with our previous data, this suggests that E2 and GEN influence 
colonocyte physiology and this state may partially explain how these compounds 
decrease risk of colon cancer. 
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CHAPTER I 
INTRODUCTION  
 In the United States, colon cancer is one of the leading causes of death. 
According to the American Cancer Society, it is estimated that in 2010 alone nearly 
51,370 people in the United States will die as a result of colon cancer. It is believed that 
colon cancer is greatly affected by hormones, particularly estrogen, as it is evident that 
women have a decreased incidence of the disease as compared to men (1). Due to this 
discovery, the use of hormone replacement therapy (HRT) has been used in an effort to 
prevent colon cancer. In fact, the majority of clinical studies have demonstrated that 
either HRT or estrogen replacement therapy can considerably lower the risk of colon 
cancer in post-menopausal women (2-7). This data is also supported by animal studies 
showing rats given estradiol (E2) had significantly fewer colon tumors by 71% (8).  
However, due to an increased risk of cardiovascular disease and breast cancer, there has 
been controversy over the use of HRT (9). As an alternative, many women have turned 
to use of dietary phytoestrogens, particularly soy isoflavones such as genistein (GEN), as 
these compounds mimic the action of estrogen. In general, epidemiological data has 
suggested that a diet rich in soy can provide chemo-protective benefits and reduce colon 
cancer risk (10).  
Although GEN has been reported to suppress colon cancer cell growth in vitro 
(11), there has been conflicting data as to whether soy isoflavones can inhibit the 
formation of colon cancer in vivo. Up to this point, all studies have used carcinogen- 
____________ 
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induced tumor formation models to determine the therapeutic effects of E2 and various 
concentrations of GEN in the diet. However, no studies to date have been focused 
specifically to the chemopreventative effects of E2 and GEN given at dietary 
concentrations in a non-malignant colon model. 
 Therefore, advancement of research in the area of evaluating how isoflavones 
influence the formation of colon cancer has been limited since most studies employ 
models of tumor progression instead of tumor prevention.  With the primary interest of 
colon cancer prevention, we are thus focused on the effects of E2 and GEN in normal, 
healthy colonic tissue given at physiologically relevant concentrations. Data from our 
laboratory demonstrate that E2 inhibits cell growth through induction of apoptosis in 
Young Adult Mouse Colonocytes (YAMC), a non-malignant cell line. This modified 
physiology is believed to result in fewer preneoplastic lesions and thus decreased risk of 
colon cancer (12).  
 Based on these data, we hypothesized that E2 and dietary concentrations of GEN 
would alter the physiology of these non-malignant colonocytes by inhibiting cell growth 
and that this response would lead to decreased risk of colon cancer. Furthermore, we 
hypothesized that this induction of apoptosis was via the p53 pathway, a pathway known 
to be induced by E2 in other tissues (13). To test our hypotheses, we characterized the 
effects of GEN in YAMCs and in healthy mice.  
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CHAPTER II 
LITERATURE REVIEW  
Research Justification 
Colon Cancer. Colon cancer involves the formation of malignant lesions in the 
large bowel and is a multi-step process progressing to an invasive stage over many years. 
The intestinal colonic epithelium is organized into small u-shaped invaginations called 
crypts that open into the intestinal lumen. The configuration of these crypts allows for 
increased surface area and thus increased nutrient absorption capabilities. In normal 
colonic tissue, stem cells at the bottom of the crypt give rise to epithelial cells (14).  A 
single layer of these epithelial cells line the colonic crypts and provide the absorptive, 
secretory, and barrier functions attributed to the large intestine. As the epithelial cells 
differentiate, they travel up the crypt wall towards the lumenal surface away from the 
area of active proliferation where cell growth occurs.  Once they have reached the 
lumenal surface, the epithelial cells may undergo apoptosis and/or are sloughed off and 
excreted into the fecal stream (14-16).  Apoptosis is the process of programmed cell 
death and is primarily initiated via two pathways.  One pathway in particular, the 
intrinsic pathway, is often triggered due to DNA damage or other types of cellular stress.  
This pathway involves the release of intracellular pro-apoptotic proteins that activate 
caspases, a group of proteases that break down proteins critical to cellular structure and 
survival (17).  In healthy colon tissue, apoptosis is generally localized to the lumenal  
region of the crypt and occurs in fully differentiated cells (18).  However, when DNA 
damage occurs, the epithelial cells undergo apoptosis closer to the zone of proliferation 
as a defense mechanism to get rid of the damaged cell before it has a chance to undergo 
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a malignant transformation (19). Thus, one of the primary functions of these epithelial 
cells is to sustain a highly-regulated balance of cellular proliferation and apoptosis. 
When there is any slight alteration of this controlled balance, malignant transformations 
can occur, possibly leading to tumorigenesis (20). 
 Carcinogenesis in humans often involves several genetic mutations that 
transform normal cells into a malignant phenotype. Typically, distinct morphological 
characteristics lead to cancer being distinguished by a continuum of three stages: 
initiation, promotion, and progression. The initiation stage of colon carcinogenesis is 
characterized by a change in the genetic makeup of a cell due to a carcinogen interacting 
with DNA, causing damage, and thus producing DNA lesions or adducts. These lesions 
lead to changes in DNA structure which can initiate genetic alterations such as the 
mutational activation of oncogenes or the silencing of tumor suppressor genes like p53 
(20-22). The p53 protein is a primary tumor suppressor found in the nucleus of the cell 
and initiates many physiological functions within the cell.  These include initiation of 
cellular senescence, induction of apoptosis, and initiation of DNA repair mechanisms in 
response to varying forms of cellular stress (23). The tumor suppressor protein p53 is a 
primary mediator of the intrinsic apoptotic pathway. Cancer progression often involves 
loss of heterozygosity in wild type p53 or dominant negative mutations. Point mutations 
in p53 occur in approximately 50% of colorectal carcinomas (24-28). These 
modifications could allow cells to hyper-proliferate and escape apoptosis (21, 29-32), 
and are thus considered precancerous. However, these mutations are frequently repaired 
during DNA synthesis and thus do not advance to the promotion stage of carcinogenesis. 
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Whenever DNA repair or apoptotic removal fails to eliminate mutated colonocytes, then 
the cells are stimulated to grow and divide faster leading to a population of benign cells. 
During the progression stage of carcinogenesis, there is clonal expansion of initiated 
cells that accumulate more DNA damage and consequently gain a selective growth 
advantage. The crypts of these cells become larger and are abnormally shaped. Their 
accumulation often results in a malignant phenotype. Groupings of these abnormal 
crypts are called aberrant crypt foci (ACF), and evidence suggests that these foci are pre-
neoplastic lesions of colon cancer (21, 29). Studies also reveal that colonocytes lining 
ACF have increased rates of proliferation (33-35), and do not undergo apoptosis (33, 34, 
36). Therefore, chemo-protective agents that decrease the rates of proliferation and 
increase the rate of apoptosis of colonocytes could lead to a decrease in colon cancer 
incidence. 
Estrogen. One chemo-protective agent that has gained much attention in relation 
to colon cancer is estrogen. Estrogens are steroid hormones typically associated with the 
human female reproductive cycle. Although the oncogenic effects of estrogen have been 
extensively studied in breast cancer, little is known about estrogen signaling in colorectal 
cancer. The protective effects observed with estrogen treatment in colon cancer are 
compelling as it has become evident that men are more susceptible to this cancer than 
women (37). Similarly, there is a general decrease in risk of colon cancer associated with 
use of hormone replacement therapy (HRT) in post-menopausal women.  Many clinical 
studies have observed a decrease in coloncancer risk associated with HRT in post-
menopausal women (2, 6, 38).  In one study, a 30-40% decrease in colon cancer risk has 
been associated with those currently using HRT.  The greatest effect was seen in those 
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using HRT for five or more years but the effect was lost after HRT use was stopped (5).  
Estrogen replacement therapy (ERT) has also been shown to decrease risk of colon 
cancer in some studies (3), but other reports show inconclusive results.  Though a 
significant protection against tumor formation has been demonstrated, these therapies are 
not currently recommended for chemoprevention of colon cancer in clinical practice due 
to their potential to increase risk of breast cancer and cardiovascular disease (9). 
Although these therapies are not currently used for chemoprevention, the studies into 
their effects are critical to understanding how they work in the colon.  
 Estrogen functions by diffusing from the serum through the lipid bilayer to the 
intracellular space where estrogen receptors (ER) reside. These receptors, ERα and ERβ, 
are maintained in a state of transcriptional inactivity within the cell through their 
interaction with co-repressor molecules (39). The binding of the primary estrogen, 17β-
estradiol (E2), to these receptors leads to a conformational change in which the receptor 
disassociates from the co-repressors and may recruit co-activator molecules (40). This 
newly activated complex then binds to an estrogen-response element on target DNA 
causing increased transcription of the target genes (41). This in turn leads to estrogen 
affecting the growth, differentiation, and function of its target tissues. 
 Animal models have long been used to study colon cancer and other diseases. 
Animal studies support the theory that E2 treatment reduces the risk of colon cancer. One 
such study revealed that E2 treatment in ovariectomized (OVX) rats exhibited reduced 
tumor development in a dimethylhydrazine induced model of colon cancer (8).  In an 
effort to determine E2’s role in the reduction of colon cancer, researchers began to focus 
on the hormone and its primary receptors. The nuclear receptor, ERα, was first identified 
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in rat uteri in 1966 (42). However, in 1996, Kuiper et al found a second estrogen 
receptor, ERβ, which was first characterized in rat prostate and ovary tissue (43, 44). 
Structurally, the two estrogen receptors ERα and ERβ have similar DNA-binding and 
ligand-binding domains, but are otherwise very different. The internal ligand-binding 
compartment is greatly conserved and only differs in two contact residues (45). 
Although this may explain the similar affinities of endogenous E2 to these receptors, 
many ligand-binding assays and ligand-competition experiments demonstrate that 
estrogens and phytoestrogens have a greater affinity for ERβ than ERα in the colon (46).  
In a study performed by Guo et al., ovariectomized wild-type (WT) and ERα knockout 
mice were orally administered estrone, a naturally occurring estrogen. Both WT and 
ERα knockout mice given estrone had decreased formation of carcinogen induced 
tumors suggesting that ERα is not the primary mediator for estrogenic protection in the 
colon (47). However, other studies have shown that ERβ expression is inversely 
associated with tumor incidence in the colon (48, 49). Research into the protective 
transcriptional effects of estrogen has typically concentrated on two main ideas: 
induction of apoptosis and inhibition of cellular proliferation in carcinogen treated 
models. Studies of ovariectomized mice show that E2 has an inhibitory effect on colonic 
epithelial cell mitotic activity (50, 51).  Weige et al. demonstrated the protective effects 
of E2 through ERβ during the initiation/promotion stages of colon carcinogenesis, as 
protection against preneoplastic lesions was lost in ERβ knock-out mice (12). The 
possibility that ERβ has anti-proliferative activity independent of ERα inhibition was 
investigated in a transgenic mouse model (48). Min/+ mice have a germ line mutation in 
a tumor-suppressor gene and are thus useful in the modeling of intestinal tumorigenesis. 
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Usually, only about 5% of these mice develop colon tumors. However, 63% of mice that 
were estrogen-receptor β deficient developed at least one colon tumor. Histological 
analysis revealed increased rates of proliferation and decreased differentiation of the 
colonic mucosa. It must be noted however that the described effects of E2 in vivo are 
protective or treatment effects as these models make use of carcinogen or a mutated gene 
and do not focus on how a normal colon responds to E2 treatment. 
It is well noted that animal models play a vital role in cancer research.  However, 
in vitro cell culture systems provide powerful models to discover and study mechanistic 
pathways responsible for phenotypic alterations seen in vivo. In regards to colon cancer 
prevention, it is believed that the primary effects of E2 through interaction with ERβ in 
the colon are to induce apoptosis and decrease proliferation. However, there has been 
conflicting data in regards to the true effects of E2 in colon cancer cell lines. A few 
studies have shown that E2 treatment can reduce cell growth in three colon cancer cell 
lines, DLD-1, HCT116, and LoVo (52-54). In the Martineti study, it was revealed that 
over-expression of ERβ in human colon tumor 118 cells decreased cellular proliferation 
when the cells were treated with E2. These effects were evident in an ERβ concentration-
dependent fashion (54). On the other hand, induction of apoptosis by E2 has been 
described via differing mechanisms including increased DNA fragmentation in 
COLO205 colon cancer cells (55). It is believed that one method behind this effect may 
be due to upregulation of the pro-apoptotic BAXα gene (56). However, other researchers 
have determined that E2, acting through ERβ, can also induce apoptosis in LoVo colon 
cancer cells through increased p53 signaling. p53 regulates the cell cycle and can induce 
apoptosis through upregulation of caspase 8 and 9. It has also been proposed that p53 
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causes a reduction in β-catenin proteins which inhibit cellular proliferation (57). 
Regardless of the precise mechanism, The E2–ERβ complex appears to activate caspase 
3, inducing the caspase-dependent pro-apoptotic cascade, thus protecting against 
disordered cell division and carcinogenesis in the colon (58). However, it must be noted 
that the majority of cell culture studies have shown that fully transformed colon cancer 
cell lines are not responsive to E2 treatments (12, 59-61). Arai et al. showed that E2 did 
not influence cell growth in various HT29, Colo320, Lovo, SW480, and HCT116 colon 
cancer cell lines (62). Likewise, Gilad et al. demonstrated that E2 did not affect cellular 
proliferation of HT29 cells (63, 64). Thus further work in this area using non-ransformed 
cells could prove valuable.   
Soy and Genistein. People from Southeast Asia appear to have much lower 
incidence of breast, prostate and colon cancer compared to Americans and Western 
Europeans (64). This trend has lead many scientists to believe that there is a diet 
association between these cultures and decreased risk of these cancers (65). After 
critiquing many epidemiological studies, it is believed that soy is the primary component 
of the Asian diet that is responsible for this decreased cancer effect (66-68).  The active 
compounds in soy are believed to be isoflavonoids, which are polyphenolic secondary 
metabolites that produce hormonal activity in mammals (69). Many of these 
isoflavonoids exhibit estrogenic action as they preferentially bind to ERβ, stimulate the 
receptor and induce an estrogenic effect (70). Thus, these compounds are commonly 
known as phytoestrogens. In foods, phytoestrogens typically occur as inactive precursor 
molecules that undergo metabolic conversions by microflora in the intestine, resulting in 
the formation of absorbable, hormone-like compounds. The particularly active 
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isoflavones genistein, daidzein, and glycitein are thus formed by hydrolysis of their 
respective glycosides, called genistin, daidzin, and glycitin, which soybeans are notably 
rich in (71). With the knowledge of the effects of estrogen in decreased rates of colon 
cancer, looking into the role of phytoestrogenic soy isoflavones seemed a logical step for 
researchers to pursue.  
 During the late 1970s scientists began to look at soy and its effectiveness in 
reducing cancers in an animal model. Two studies used female F344 rats (72) and male 
Sprague-Dawley rats (73) to examine the effects of soy protein feeding on DMH-
induced colon carcinogenesis. However, both studies failed to find significant 
differences in tumor number or incidences between the control and soy diet groups. 
Another study using endoscopic inspection of azoxymethane(AOM)-treated F344 rats 
reported decreased incidence of colorectal tumors in animals fed diets either containing 
soybean curd or soy protein digest when compared with those fed using the control 
casein diet (74). In the Hakkak et al. study (75), effects of soy protein isolate containing 
430 mg total isoflavones per kilogram diet was investigated against AOM-induced colon 
tumor formation in male Sprague-Dawley rats. Results showed a prominent decrease in 
incidences of both benign (5 versus 19%) and invasive (10 versus 31%) tumors when 
compared with controls. It must be noted however that experimental diets were 
previously administered to parental animals, suggesting that long-term consumption of 
soy protein may be required to diminish the risk of colon cancer. 
  For the most part, these experiments looked at soy as a whole and not the 
individual isoflavones effects. Unfortunately, only a few in vivo studies involving 
isolated phytoestrogens have been executed, and most of these focused on genistein due 
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to the discovery in 1987 that pharmacological levels of genistein, the primary isoflavone 
found in soy, inhibited the activity of the epidermal growth factor receptor tyrosine 
kinase in vitro, thus reducing cell growth (76). Many receptor tyrosine kinases are 
involved in oncogenesis by gene mutation, chromosomal translocation or over-
expression. With about 50% of the oncogene protein products being membrane bound 
receptors with tyrosine kinase activity, it is believed that genistein is the isoflavone in 
soy responsible for anti-cancer effects when at concentrations larger than 10 µM (77). 
Genistein also has a structure very similar to E2 and thus acts like the hormone through 
binding with ERβ, possibly exerting chemo-protective effects (46).  Furthermore, 
genistein has been found to have anti-angiogenic effects and may block the uncontrolled 
cell growth associated with cancer cells (78). Thus since this revelation, genistein has 
been widely studied in both in vitro and in vivo models to determine its effect on various 
cancers.  
 Clark et al. (79) were the first to investigate in vitro effects of genistein on 
colonic cancer cells. This study revealed that 1, 5, and 10 μM of genistein dose-
dependently repressed growth of HCT-8 human colon cancer cells by 12, 28, and 100%, 
respectively. Then in 1993, Yanagihara et al. (80) examined possible anti-proliferative 
effects of genistein on a number of colon cancer cell lines. Genistein given at 
concentrations of 11.5 µM and 9.5 µM strongly inhibited proliferation in HCC-48 and 
HCC-50 colon cancer cell lines respectively. It was also noted that at above 150 μM, a 
pharmacological concentration that could never be achieved via the diet, genistein 
induced a significant increase of DNA strand breaks believed to be due to increasing the 
rate of topoisomerase II-mediated DNA cleavage (81). Recently, Plewa et al. (82) 
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measured suppression of growth rate of HT-29 cells by treatment with genistein and 
daidzein. Genistein at 11.5 μM and daidzein at 25 μM significantly suppressed cell 
growth due to cell cycle arrest mechanisms. As most of these data point to genistein 
potentially being an effective chemo-preventive agent, one must consider the fact that 
the concentrations used above are of supplemental value and are thus difficult to obtain 
via diet alone.  
 With in vitro data suggesting that genistein could prevent colon carcinogenesis, it 
became necessary to determine if the same effects could be observed in vivo. The first 
study that investigated an isolated phytoestrogen in vivo looked at genistein’s effects in 
an AOM-induced carcinogenesis model using male F344 rats. Genistein proved to be a 
potent isoflavone against development of aberrant crypt foci (ACF). A diet consisting of 
75 and 150 mg/kg genistein was shown to be sufficient to yield a statistically significant 
reduction of ACF number (83). Helms and Gallaher (84)observed similar results in male 
Wistar rats. DMH-induced ACF formation was decreased up to 35% with a diet 
containing up to 372 mg/kg genistein. Finally, Thiagarajan et al. (85) found that 
genistein inhibited ACF formation by 40% compared to a diet containing soy protein 
concentrate with a very low isoflavone content in AOM-treated rats. As these studies 
show a correlation between genistein and decreased colon tumor incidence, there are 
however other studies that do not show such an effect. One such study performed by Gee 
et al. (86) used diets enriched with genistein at 250 mg/kg diet. Consumption of diet 
before treatment with DMH was coupled with a two to threefold increase in ACF 
development of the rat colon, but there was no effect observed when the genistein was 
given after treatment with DMH. In spite of the large number of already performed in 
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vivo and in vitro studies on a potential positive effect of phytoestrogens, particularly 
genistein, against the development of colorectal cancer, much work is still needed. 
Studies need to begin to focus on the effects of such phytoestrogens in normal, healthy 
systems as a chemo-preventative model before recommendations with respect to 
phytoestrogen consumption by humans can be made. 
Hypothesis. Estradiol and genistein given at dietary concentrations decrease 
cellular proliferation and induce apoptosis via the p53 pathway in normal, healthy colon 
tissue and thus prove to be effective chemo-preventive agents. 
Specific Aims. The objectives of this study were to:  
1.  Determine if estradiol and genistein downregulate proliferation in mouse 
colonocytes.      
2.  Determine if mouse colonocyte apoptosis is induced by estradiol or 
genistein. 
3.  Determine if estradiol and genistein utilize the p53 pathway to induce 
apoptotic effects in mouse colonocytes.   
  
 
 
 
 
 
 
 
 
13 
 
13 
 
 
13 
14 
 
CHAPTER III 
ESTRADIOL AND GENISTEIN ALTER CELLULAR PHYSIOLOGY OF NON-
MALIGNANT COLONOCYTES 
Introduction 
 In the United States, colon cancer is the third most prevalent malignancy and 
ranks third among cancer related deaths. Women have a decreased incidence of colon 
cancer (43.6 in 100,000) as compared to men (59.0 in 100,000), suggesting a possible 
protection against the disease due to hormonal changes (1). Data from the Women’s 
Health Initiative Study showed a significant reduction in the incidence of colorectal 
cancer in post-menopausal women receiving hormone replacement therapy (HRT) 
compared to placebo control (9). In fact, the majority of clinical studies have 
demonstrated that either HRT or estrogen replacement therapy can significantly decrease 
the risk of colon cancer in post-menopausal women with no significant difference in 
effect between the two therapies (2-7). Clinical data are also supported by animal studies 
showing rats given estradiol (E2) had significantly fewer colon tumors by 71% (8).  Data 
from our laboratory suggest that the protective effect of E2 in the colon begins at early 
stages of tumor formation, as ovariectomized mice receiving an E2 implant had fewer 
preneoplastic lesions in the colon when compared to control animals (12).   
 However, there has been controversy over the use of HRT as women receiving 
therapy had increased risk of invasive breast cancer (9). One alternative to HRT that 
women have turned to is use of dietary phytoestrogens, with the most common class 
being soy isoflavones. In general, like HRT, epidemiological data suggests that soy 
reduces colon cancer risk (10). A recent meta-analysis demonstrated that, in women, 
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consumption of soy significantly reduced incidence of the disease indicating gender 
specificity for the protective effects of the dietary component (87). Soy isoflavones 
which have a chemical structure similar to E2, such as genistein (GEN), mimic the 
hormone by binding to estrogen receptors and thus eliciting estrogenic responses in 
multiple tissue types.  
GEN has also been reported to suppress colon cancer cell growth in vitro (11). 
However, there has been conflicting data as to whether soy isoflavones can inhibit the 
formation of colon cancer in vivo.  In a study performed by Sorensen et al., a soy 
isoflavone diet did not protect against intestinal tumor development in the Min mouse 
model (88). Conversely, as seen in E2-treated models, isoflavone containing diets have 
been shown to reduce the number of aberrant crypt foci, which are considered to be 
preneoplastic lesions (89, 90). All studies thus far have used carcinogen-induced tumor 
formation in combination with continuous exposure to either E2 or GEN containing diets 
to determine the chemotherapeutic effects of the compounds. However, no studies to 
date have reported how E2 or GEN given at physiologically relevant concentrations 
might impact colonic epithelial cell function in the absence of carcinogen associated 
damage and/or eventual malignancy. 
 Therefore, advancement of research in the area of evaluating how E2 and 
isoflavones influence the formation of colon cancer has been limited since most studies 
use tumor models and focused analysis to later promotion and/or progression stages of 
the disease. However, to truly elucidate their protective roles in the colon, it is 
imperative that we understand how these compounds influence cell physiology prior to 
becoming cancerous. As such, the presented studies objectives were to examine the 
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effects of E2 and GEN at physiological concentrations on non-malignant colonic 
epithelia. To do so, both in vitro and in vivo analysis were conducted and for the first 
time we report that these estrogenic compounds can alter the physiology of colonocytes 
in the absence of disease.  
Materials and Methods  
Cells.  Young Adult Mouse Colonocytes (YAMC) cells were supplied by Dr. 
Robert Chapkin (Department of Nutrition and Food Science, Texas A&M University, 
College Station, TX). These cells are a well-characterized non-malignant cell line 
derived from the Immortomouse, and are morphologically primitive epithelial cells with 
no evidence of differentiation. YAMC cells are conditionally immortalized by the 
expression of the temperature-sensitive SV40 large T antigen, and do not form tumors in 
athymic mice (91). For regular maintenance, cells were cultured in RPMI 1640 media 
(Sigma-Aldrich; St. Louis, MO) with 5% fetal bovine serum (FBS; HyClone; Logan, 
UT); 1% penicillin/streptomycin; 1% Glutamax-1 (Invitrogen; Carlsbad, CA); and  0.1% 
insulin, transferrin, and selenious acid (ITS; BD Biosciences; Franklin Lakes, NJ). Cells 
were maintained under permissive conditions, 33˚C with 10 units interferon gamma 
(IFNγ) (Roche; Indianapolis, IN) per milliliter medium.   
Cell Growth Assays. Forty-eight hours before plating, YAMC cells were 
transferred to medium containing 5% charcoal-dextran-stripped FBS, 1% 
penicillin/streptomycin, 1% Glutamax, and 0.1% ITS and were maintained at non-
permissive conditions, 39˚C and without IFNγ. Cells were then seeded at 30,000 cells 
per well on a six-well plate. Twenty-four hours after plating, cells were given individual 
treatments of 1 nM/L E2, 1 µM/L GEN, or 10  µM/L GEN. All treatments were diluted 
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in DMSO as 1,000x stocks and delivered as 1 µL/mL medium to achieve the final 
concentration listed. Forty-eight hours after the first treatment, the medium was changed 
and a second dose of the given treatments was delivered.  At the end of the 96 h 
treatment period, the cells were trypsinized and prepared for counting. Cell 
concentrations were determined using a Beckman Coulter particle counter. Twenty µL 
of sample was diluted in 10 mL Isotone II diluent (Beckman Coulter), and each sample 
was counted three times. Three wells per treatment per experiment were used and three 
replicate experiments were conducted.   
Cellular Proliferation. YAMC cells were grown under non-permissive 
conditions in stripped serum medium for 48 h before plating. Cells were then seeded at 
2,000 cells per well on a 96-well plate and allowed to adhere overnight. Treatments of 1 
nM/L E2, 1 µM/L GEN, or 10  µM/L GEN were given for 96 h and medium changed 
every 48 h. Bromodeoxyuridine (BrdU) label, from the CalBiochem BrdU Cell 
Proliferation Assay (QIA58) kit (Calbiochem; Gibbstown, NJ), was added at hour 78 
and allowed to incubate for 18 h. BrdU is a synthetic nucleoside that is analogous to 
thymidine and is thus incorporated into the DNA of newly synthesized replicated cells. 
The BrdU kit protocol was then followed for the remainder of the procedure. 
Proliferation was measured as increased fluorescence measured on a TECAN Infinite 
M200 plate reader at dual wavelengths of 450 and 595 nm. Three wells per treatment per 
experiment were used and four replicate experiments were conducted.  
Cellular Apoptosis.  YAMC cells were grown under non-permissive conditions 
in stripped serum medium for 48 h before plating. Cells were seeded at 30,000 per well 
on six-well plates and treated for 96 h with treatments of 1 nM/L E2, 1 µM/L GEN, or 10  
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µM/L GEN and medium changed every 48 h. At the end of the treatment period, cells 
were trypsinized and collected. After collection, the cells were centrifuged and the 
medium was replaced with lysis buffer from the EnzChek Caspase-3 Assay Kit No. 2 
(Invitrogen). The Invitrogen protocol was followed for this procedure. Relative 
apoptosis was determined by fluorescence intensity measured on a TECAN Infinite 
M200 plate reader. Three wells per treatment per experiment were used and four 
replicate experiments were conducted.   
p53 Reporter Assay.  YAMC cells were seeded at 10,000 cells per well on 12-
well plates in stripped medium and grown under non-permissive conditions for 72 hrs. 
After 48 h, cells were transiently transfected with 0.5 µg β-galactosidase (β-gal) and 4 
µg pG-13, a basic luciferase (Luc) reporter construct containing three upstream copies of 
a synthetic p53 response element, per plate using Effectene Reagent (Qiagen; Valencia, 
CA). Cells were then treated with 1 nM/L E2, 1 µM/L GEN, or 10  µM/L GEN for the 
final 18 h. After the 18 hr treatment period, cells were lysed using 200 µL Reporter 
Lysis Buffer (Promega; Madison, WI) and Luc and β-gal assays (Promega) were 
conducted to quantify p53 activity and transfection efficiency, respectively using Luc to 
β-gal ratios and a TECAN Infinite M200 plate reader. Six wells per treatment per 
experiment were used and four replicate experiments were conducted.   
Animal Study Design. c57BL6/J mice were obtained from The Jackson 
Laboratory. Mice were housed and bred at the Laboratory Animal Resources and 
Research facility at Texas A&M University. All procedures were performed under a 
protocol approved by the Institutional Animal Care and Use Committee at Texas A&M 
University. On day one, 30 female mice were individually housed, randomly assigned to 
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a control, E2, or dietary GEN treatment group based on age and weight, and given a 
semi-purified pellet diet (AIN-76, Harlan; Indianapolis, IN). On day sixteen, all mice 
were ovariectomized and control and GEN mice were given a 20 mg cholesterol (Sigma) 
pellet while E2 mice were given a 19 mg cholesterol/1 mg E2 pellet implanted s.c. on the 
back at the base of the neck. On day 30, all mice were switched to a semi-purified 
powder diet given in individual bowls to allow the animals to acclimate to powder diet. 
GEN treatment group mice were switched to a 1,000 ppm GEN powder diet on day 44 
and sacrifice occurred on day 72. At time of sacrifice, blood was collected through 
cardiac puncture and the uterus was placed in 4 mL 1X PBS for subsequent weighing. 
The colon was resected and 1-cm sections from the distal end were cassetted and fixed in 
4% paraformaldehyde. Food intake and fecal collection was taken once per week to 
determine difference in intake. To ensure accurate consumption values, food intake for 
individual mice was determined by measuring amount of diet given in each bowl minus 
the amount left in each bowl and spillage. No significant differences in food intake were 
observed between treatment groups.  
Colon Crypt Height. Using photos taken at 400x of sections from the apoptosis 
analysis described below, colon crypt height was measured for 20 crypts from each 
mouse. Each measurement was taken from the base of the crypt to the top of the crypt 
using ImageJ software (National Institute of Health). Height, given in inches (150 
pixels=1 inch), was subsequently converted into micrometers.  
In vivo BrdU Proliferation Assay. Detection of cellular proliferation was 
determined by using immunohistochemistry with Anti-BrdU (Roche) as a primary 
antibody and Goat anti-mouse HRP conjugated antibody (Abcam; Cambridge, MA) as a 
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secondary antibody. Two hours prior to sacrifice, animals were injected with 7.5 µL 
BrdU/g body weight. Distal colon sections were fixed in 4% paraformaldehyde 
overnight, paraffin embedded, sectioned and mounted. Tissues were deparaffinized in 
three washes of xylene and rehydrated. Slides were quenched with hydrogen peroxide 
for 30 minutes and washed in distilled (DI) water three times. Slides were prepared for 
antigen retrieval by submerging in a solution containing 9 mL 0.1 M citric acid, 41 mL 
0.1 M trisodium citrate, and 450 mL DI water and heating in a microwave on high for 10 
mins and medium for 10 mins. Slides were then washed in PBS and a 1:20 dilution of 
anti-BrdU antibody in PBS with 1% BSA was applied and left to incubate in a 
humidified chamber at 4˚C overnight. Next, tissues were washed in DI water, a 1:200 
dilution of secondary antibody in PBS with 1% BSA was applied and allowed to 
incubate in a humidified chamber for 1 h at RT.  Tissues were stained in a 1% 
diaminobenzidine (DAB) solution for 10 mins, washed in DI water five times, and 
counterstained with Hematoxylin for 15 secs. Tissues were then dehydrated and wet 
mounted using Permount. To analyze tissues, photos of 20 intact crypts per animal were 
taken at 400x using a Zeiss Axiovert 200 Microscope with an AxioCAM. Each crypt 
was then divided into a bottom, middle, and top third and the number of proliferative 
cells and non-proliferative cells were counted for each section. 
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling 
Assay. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) assays were completed using the ApopTag Plus Peroxidase In situ Apoptosis 
Detection kit (Millipore; Billerica, MA) according to manufacturer’s instructions with a 
few modifications. Briefly, distal colon sections were fixed in 4% paraformaldehyde 
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overnight, paraffin embedded, sectioned and mounted. Tissues were deparaffinized in 
three washes of xylene and rehydrated using ethanol. Endogenous peroxidase activity 
was quenched as slides were submerged in hydrogen peroxide and methanol for 30 
minutes, placed in a 0.5% DAB solution for 20 secs, washed in DI water, and 
counterstained in methyl green for 5 secs. Tissues were then dehydrated and wet 
mounted using Permount. To analyze tissues, photos of 20 intact crypts per animal were 
taken at 400x using a Zeiss Axiovert 200 Microscope with an AxioCAM. Each crypt 
was then divided into a bottom, middle, and top third and the number of apoptotic cells 
and non-apoptotic cells were counted for each section. 
Statistics. Statistics were performed using a Student’s t test or Poisson regression 
model depending on the outcome analyzed. t test analyses was performed in Microsoft 
Excel for the in vitro data. A Poisson regression model was used, with the help of Dr. 
Alan Dabney, to model our in vivo apoptosis data within the colonic crypt.  Because 
many crypts had zero counts, we allowed for overdispersion in the model.  This allows 
for flexibility in the mean: variance relationship otherwise required by the Poisson 
assumption and, in particular, permits valid statistical inference when there is greater 
variability in the data than would be expected by a pure Poisson model.  Statistical 
inference was carried out by testing model coefficients corresponding to group 
comparisons with control for each of the E2 and GEN diets, using a Wald test. 
Results 
E2 and GEN Inhibit Non-Malignant Cell Growth. First, we measured the 
effects of E2 and GEN treatment on cell growth in non-malignant colonocytes in vitro. 
YAMC cells treated with 1 nM/L E2, 1 µM/L GEN, and 10 µM/L GEN showed reduced 
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growth compared to vehicle control when treated for 96 h under non-permissive 
conditions (Fig. 1). As the GEN dose increased from 1 to 10 µM/L, there was a 
corresponding decrease in cell growth (P < 0.01).  These data demonstrate a growth 
inhibitory effect in non-malignant colonocytes exposed to physiologic levels of E2 and 
dietary levels of GEN.  
 
Fig. 1: GEN and E2 inhibit growth of YAMC cells. YAMC cells were grown at 39°C 
in the absence of IFNγ. Cells were transferred to a charcoal dextran–stripped medium 48 
h before plating. Twenty-four hours after plating, cells were treated with 1 nM/L E2, 1 
µM/L GEN or 10 µM/L GEN, and treatments were replaced 48 h later. Data are 
expressed as percentage of growth of the DMSO control group. Mean (n = 12) from four 
replicate experiments. Bars, SEM, without a common letter differ; p < 0.01.  
 
E2 and GEN Do Not Suppress Proliferation in Non-Malignant Colonocytes 
in vitro. Next, we wanted to identify the mechanism involved with E2 and GEN 
treatment and growth inhibition. To determine if inhibition of cell growth was due to a 
decrease in cellular proliferation, levels of BrdU incorporation when YAMC cells were 
treated for 96 h with 1 nM/L E2 , 1 µM/L GEN, and 10 µM/L GEN was measured (Fig. 
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2). BrdU is a synthetic analog to thymidine and can thus replace the nucleoside during 
DNA synthesis indicating cellular proliferation (92). No treatment was significantly 
different from the vehicle control indicating that directly suppressing cellular 
proliferation is not a mechanism involved in the E2 or GEN induced growth inhibition of 
non-malignant colonocytes. 
 
Fig. 2: GEN and E2 do not suppress proliferation of YAMC cells. YAMC cells were 
grown at 39°C in the absence of IFNγ. Cells were transferred to a charcoal dextran–
stripped medium 48 h before plating. Cells were treated with 1 nM/L E2, 1 µM/L GEN or 
10 µM/L GEN for 96 hours, and treatments were replaced 48 h later. BrdU label was 
added at hour 78 and allowed to incubate for 18 h. Data are expressed as mean 
absorbance +/- SEM, which directly correlates to BrdU incorporation. n = 12 from four 
replicate experiments. 
 
Apoptosis in YAMC Cells Treated With E2 and GEN. We then measured the 
role of E2 and GEN on apoptotic activity in the non-malignant colonocytes. Caspase-3 
activation was used to determine the relative number of apoptotic cells when YAMC 
cells were treated with 1 nM/L E2, 1 µM/L GEN, and 10 µM/L GEN for 96 h (Fig. 3). 
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YAMC cells showed an increase in caspase-3 activity in E2-treated cells as well as GEN 
treated cells in a dose-responsive manner (p<0.0001). These data identify induction of 
apoptosis as a primary mechanism involved in the E2 and GEN induced growth 
inhibition of non-malignant colonocytes.  
 
Fig. 3: Apoptosis in YAMC cells treated with GEN and E2. YAMC cells were grown 
under non-permissive conditions and transferred to a charcoal dextran–stripped medium 
48 h before plating. After 96 h of GEN or E2 treatment, cells were collected and the 
EnzChek caspase-3 assay was performed. Data are expressed as increased fluorescence 
measured when compared with the blank. Mean (n = 9) +/- SEM from three replicate 
experiments; bars without a common letter differ; p < 0.001. 
 
p53 Activity in YAMC Cells Treated With E2 and GEN. Having shown 
induction of apoptosis in cells treated with E2 and GEN, we next wanted to begin to 
determine pathways involved in this induction. As p53 has been shown to induce 
apoptosis in response to E2 and GEN in other cell lines, we measured p53 transcriptional 
activity in YAMC cells treated with 1 nM/L E2 ,1 µM/L GEN, and 10 µM/L GEN for 18 
h (Fig. 4). Both E2 and GEN increased p53 activity, with GEN doing so in a dose-
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responsive manner (p<0.0001). This demonstrates that E2 and GEN upregulate p53 
transcriptional activity and suggests that this induction leads to the increased apoptosis 
previously observed.  
 
Fig. 4 : GEN and E2 enhance p53 transcriptional activity in YAMC cells. YAMC 
cells were grown at 33°C and without IFNγ.  Cells were transferred to charcoal dextran 
stripped media 48 hrs prior to plating.  Cells were then grown under non-permissive 
conditions, at 39 °C, for 72 hrs.  After 48 hrs, cells were transfected with pG-13 p53 
reporter construct and β-gal construct.  Cell lysates were collected and used to perform 
luciferase and β-galactosidase assays, results were measured on a Tecan Infinite M200 
plate reader.  Data are presented as percentage of vehicle control.  Values are means +/- 
SEM, n=9.  Bars without a common letter differ, p < 0.01.  
 
Colon Crypt Height in Animals. With E2 and GEN treatment resulting in 
significant changes in YAMC cells, we next wanted to correlate the in vitro data to 
physiological effects of the estrogenic compounds in vivo. First, to determine if GEN or 
E2 induced any morphological changes in colonic tissue, we measured colon crypt height 
in mice given an E2 pellet or on a 1,000 ppm GEN diet. E2-treated animals had an 
increase in colon crypt height compared to control animals (p<0.01), with GEN animals 
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trending in the same fashion (Fig. 5). These data suggest that E2, and potentially GEN, 
alter colon crypt morphology allowing for the physiologic changes observed. 
 
Fig. 5:  Colon crypt heights of the distal colon.  Sections of distal colon were taken 
from 7 to 10 mice in each treatment grouped and stained using the TUNEL assay. This 
data represents 20 intact crypts measured, using Image J software at 400X, from the base 
of the crypt to the lumen. Bars without a common letter differ, p-values < 0.01. 
 
Proliferation Within the Colonic Crypt. Next, we wanted to investigate the 
roles of E2 treatment or GEN diet in non-malignant colonic epithelia. We began by 
exploring the effects of E2 and GEN on proliferation in the distal colon of c57BL6/J 
mice. As seen in vitro, there was no significant difference in number of proliferating 
cells in either E2-treated animals or those receiving a GEN diet as compared to control 
mice (Fig. 6). These data indicate that neither E2 treatment nor a GEN diet influences 
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proliferation with the colonic crypt of a healthy animal.   
 
Fig. 6: Proliferation within the colonic crypts of the distal colon. A BrdU 
immunohistochemistry assay was performed on sectioned tissue from the distal colon. 
Data are expressed as proportion of proliferative cells found compared with total number 
of cells found in the crypt. These data are representative of 20 well-oriented crypts per 
animal and 7 to 10 animals per treatment group. 
 
Apoptosis Within the Colonic Crypt. We then analyzed apoptosis to see if 
there was a change with E2 treatment or a GEN diet. Induction of colonocyte apoptosis 
was determined in distal colon tissues from each experimental group. Crypts analyzed 
from E2-treated animals displayed a higher degree of total apoptotic cells compared to 
the control (p=0.05), with a significant increase in the bottom third of the crypt (p<0.05). 
Mice on a GEN diet trended in the same fashion as E2-treated but did not reach statistical 
significance (Fig. 7, A and B). These data show a marked increase in apoptotic cells in 
response to E2 treatment with dietary GEN trending in the same direction. 
 
27 
 
 
28 
 
A.  
B.  
Fig. 7: Apoptosis within the total colonic crypts of the distal colon. A, total crypt. A 
TUNEL assay was performed on sectioned tissue from the distal colon. Data are 
expressed as proportion of apoptotic cells compared with total number of cells in the 
crypt. These data are representative of 20 well-oriented crypts per animal and 7 to 10 
animals per treatment group. B, bottom section of the colonic crypt. Using same animals 
and crypts, data are expressed as percentage of apoptotic cells in the bottom third 
compared with total number of cells in the bottom third of the crypt. Bars without a 
common letter differ, p ≤ 0.05. 
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Discussion 
 Due to evidence from clinical and animal model experiments, E2 has become a 
primary interest in the prevention of colon cancer. Phytoestrogens, such as GEN, appear 
to exert similar effects as E2. Several in vivo studies have shown reduced risk of colon 
cancer development when mice and/or rats are treated with E2 or their diets 
supplemented with GEN (47, 48, 66, 85). However, these studies utilize colon cancer 
induction models and since exposure to E2 and GEN was continuous from before 
carcinogen introduction until tumor collection, these studies do not distinguish 
prevention from treatment. Data previously published from our laboratory demonstrates 
that E2 inhibits formation of preneoplastic lesions in carcinogen treated animals, 
demonstrating a protective role of E2 at a pre-malignant stage of carcinogenesis (12). 
However, these previous studies also used carcinogen in vivo and thus do not allow for 
interpretation of the effects of E2 on normal colonic physiology. The primary purpose of 
the presented studies was to determine the effects of estrogenic compounds on 
colonocytes in a non-diseased state, with a primary focus on cell growth and apoptosis.  
In order to assess E2 and GEN’s role as a chemopreventative agent in the normal 
colon, it was necessary to study the effects of these compounds in non-malignantly 
transformed colonocytes in vitro and in vivo. Although in vitro studies have shown that 
E2 and GEN can reduce cell number in colon cancer cell lines such as HT-29 and DLD-1 
(11, 52, 53, 56, 62, 93), this data is controversial as E2 data cannot often be reproduced 
and those using GEN frequently treat with pharmacologic doses. For the first time we 
reveal that E2 and dietary relevant concentrations of GEN can change the growth of non-
malignant colonocytes by showing a significant reduction in cell number in YAMC cells 
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treated with E2 and GEN. This response was observed in YAMC cells maintained at 
non-permissive conditions (see methods for details), suggesting these compounds can 
exert their effects in primordial colon cells which have undergone very few population 
doublings and are therefore more representative of normal colonic epithelia. Having 
observed reduced cell number in these non-transformed cells, we next wanted to 
determine if this response was due to suppression of proliferation or increased apoptosis. 
While some in vitro studies show decreased rates of proliferation with increased rates of 
apoptosis in nasopharyngeal and glioma cell lines, other cell lines such as LoVo and 
SW620 showed no effect when treated with physiologic levels of E2 or dietary levels of 
GEN (11, 55, 94, 95). Once again, the cell lines utilized in these studies were malignant 
and thus only allow interpretation for chemotherapeutic effects of E2 and GEN and not 
protective effects. One study, nonetheless, did show that GEN could inhibit cellular 
proliferation and induce apoptosis in non-transformed intestinal cells, IEC-6 and IEC-18, 
which are derived from the ileum (96).  In contrast, we observed no significant 
difference in proliferation rates for colonocytes (YAMCs) treated with E2 or GEN as 
compared to vehicle control. Conversely, we did observe significant induction of 
caspase-3 activity in YAMC cells in response to both E2 and GEN treatment in a dose-
dependent manner. These data demonstrate that both E2 and GEN reduce cell growth in 
noncancerous colonocytes by induction of apoptosis and suggest that small and large 
intestinal epithelia may respond differently to estrogenic compounds.  
 To begin to investigate the mechanism of action inducing apoptosis, we wanted 
to determine if E2 and GEN could induce the p53 activity in YAMC cells. p53 is a 
commonly known tumor suppressor gene that regulates the cell cycle and can induce 
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apoptosis (23). Point mutations in p53 have also been linked to colon carcinomas (24, 
25, 28). Therefore, it was logical that we begin to look into p53’s potential activation by 
E2 and GEN. There has been evidence suggesting both E2 and GEN can upregulate 
expression of p53 mRNA levels in various cell lines including lung cells and osteoblasts 
(97-99). Wilson et al. also demonstrated that GEN can increase p53 protein levels in 
HCT-116 cells, a colorectal carcinoma cell line (100). Consequently, we investigated the 
effects of E2 and GEN in the YAMC’s and observed a significant increase in p53 
transcriptional activity following these two treatments in a dose-dependent manner. This 
data suggests that E2 and GEN can directly enhance p53 transcriptional activity in non-
malignant colonocytes, and this induction is likely the underlying cause of apoptosis 
observed in YAMC cells. Additional experiments are required to confirm these findings 
and to determine the relevant downstream targets of p53 that are modulated by E2 and 
GEN.  
 With our in vitro data suggesting a change in colon cell physiology due to E2 and 
GEN, we next wanted to determine if these effects are apparent, and thus predictive, in a 
non-carcinogenic in vivo model. Methodology was utilized that we have routinely used 
in the past (12, 101, 102) to deliver physiologically relevant concentrations of E2. Mice 
receiving an E2 pellet had serum levels averaging 0.80 nM/L, which is slightly lower 
than E2 levels observed in a nonpregnant cycling woman (103, 104). Control and GEN 
animals receiving a cholesterol pellet were below the threshold associated with 
menopause in women (105). For delivery of GEN in the diet, we again used 
methodology and dietary concentrations routinely used in our laboratory and others 
(17,41, 106). This GEN containing diet known to produce plasma GEN levels in mice 
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that are equivalent to circulating levels found in humans consuming a soy diet (101, 107-
110).   
 We first wanted to determine if E2 and GEN caused gross morphological changes 
in the colon that could be attributed to an alteration in colonic physiology, we measured 
colon crypt height. No studies have demonstrated that E2 or GEN cause any significant 
change in morphology of the colon. However, in mice treated with the inflammatory 
chemical dextran sodium sulfate, crypt distortion occurs leading to a decrease in colon 
crypt height (111). Mice receiving E2-treatment had increased colon crypt heights 
compared to control animals with GEN trending in the same fashion. This suggests that 
E2 may be providing a pre-emptive, protective mechanism against possible inflammation 
in the colon while allowing greater nutrient absorption. Further studies are needed to 
deduce the reason for these morphological changes.  
 As seen in vitro, when examining each sectional third of the crypt (top, middle 
bottom), there was no difference in overall proliferation rates among the three treatment 
groups (data not shown). Although studies have shown a decrease in cellular 
proliferation in mice treated with carcinogen and receiving E2 or GEN treatments (112), 
there is no such trend observed in a healthy, non-transformed colonocyte. Likewise, we 
have demonstrated that the cell cycle is not altered in YAMCs treated with E2 (12). 
While confirming what was observed in vitro, data from this study suggest the larger 
finding that altering the rate of cellular proliferation is not a primary mechanism of 
estrogen suppression of tumor formation.  
 Finally, knowing that E2 can elicit apoptotic effects in chemically transformed 
tissues, we wanted to ascertain if apoptosis is induced in the colonocytes of healthy 
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animals treated with E2 or given a GEN diet. As demonstrated in vitro, E2 and GEN 
treated mice expressed higher rates of apoptosis throughout the depth of the crypt, 
although not statistically significant. However, E2 treated animals did have a significant 
increase in the number of apoptotic cells in the bottom third of the crypt with GEN 
trending in the same fashion. With a larger number of GEN animals, we believe we 
could have seen a statistically significant effect from GEN as well. Hall et al. noted that 
in colon tissue not receiving experimental treatments, apoptosis is generally localized to 
the lumenal region of the crypt as this is the region where differentiating cells migrate 
and are thus sloughed off (18). However, in response to DNA damage resulting from 
carcinogen treatment, studies from our laboratory demonstrate that when you treat with 
E2, apoptosis is upregulated in the bottom third of the crypt as early as 12 hours post (in 
press) and up to 8 weeks after carcinogen exposure (12). As the bottom third of the crypt 
is the zone of actively proliferating cells, these data suggest that E2 and GEN alter the 
physiology of this important area even in a non-diseased state. Furthermore, because 
these tissues are healthy and show no pathological signs of disease, we would not expect 
large physiological shifts in apoptosis. This relatively modest increase in number of 
apoptotic cells, primarily in the bottom third of the crypt,  indicate that E2 and potentially 
GEN might provide protective effects against colon cancer by eliminating damaged cells 
via apoptosis prior to them becoming fully initiated and transformed.   
 In conclusion, GEN and E2 treatments showed unique changes in YAMC cells 
and non-malignant colonocytes in vivo. Treatment with E2 and GEN diet reduced cell 
growth, had no effect on cellular proliferation, and induced apoptosis via activation of 
the p53 pathway in non-malignant colonocytes in culture. Additionally, in 
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ovariectomized mice receiving no carcinogen treatment, E2 resulted in no change in 
cellular proliferation, but apoptosis in colonocytes was induced with dietary GEN 
trending in the same fashion. For the first time, these data indicate that E2 treatment and 
dietary levels of GEN can change the physiology of normal colonic tissue by inducing 
apoptosis in a non-transformed colonocyte. It is likely that these alterations in cellular 
physiology contribute to the protective effects against the development of colon cancer 
by eliminating damaged cells. These findings are primary steps toward identifying the 
roles of E2 and GEN in non-malignant colonocytes and provide insight into their 
potential chemoprotective effects. 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 Witch colon cancer being the third most prevalent malignancy in the United 
States, it has become increasingly important to understand the disease and study possible 
mechanisms of its prevention. Many studies have begun this task by looking into the 
roles of E2 and GEN in colon cancer prevention. However, the investigations up to date 
utilize carcinogen-induced models and thus are truly examining chemo-therapeutic and 
not chemo-protective effects. Thus, in an effort to elucidate the physiologic effects of E2 
and dietary GEN on healthy colonic tissue, we studied these compounds in non-
malignantly transformed colonocytes in vitro and in vivo. We began by determining the 
effects these compounds have on cell growth. For the first time, we reveal that E2 and 
dietary relevant concentrations of GEN can alter the growth of non-malignant 
colonocytes by showing a significant decrease in cell number of YAMC cells treated 
with these compounds. With an evident change in cell number, we sought to determine if 
this response was due to suppression of proliferation or induction of apoptosis. While a 
few studies have shown decreased rates of proliferation and increased rates of apoptosis 
in various colon cancer cell lines treated with E2 and/or GEN, in regards to healthy colon 
tissue, we observed no significant difference in proliferation rates for YAMCs treated 
with E2 or GEN as compared to vehicle control. However, we did observe a significant 
increase in induction of apoptotic activity with increased levels of Caspase-3 in YAMCs 
treated with E2 and GEN. These results were evident in a dose-dependent manner, 
suggesting that both E2 and GEN can reduce cell growth via induction of apoptosis in 
noncancerous colonocytes.   
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 As induction of apoptosis appeared to be the mechanism involved in reducing 
colon cell growth, we then investigated the pathway behind this induction. Via use of a 
p53-reporter assay, it appears as though both E2 and GEN directly enhance p53 
transcriptional activity in non-malignant colonocytes, and that this induction is likely the 
fundamental cause of the apoptosis observed in the YAMC cells.  Finally, with the in 
vitro data suggesting a change in colon cell physiology due to treatment with E2 and 
GEN, we utilized a non-diseased state in vivo model to determine if we could observe 
the same effects. The in vivo data proved to be consistent with our in vitro data as 
normal, healthy mice receiving E2 treatment or a GEN diet did not have a significant 
change in colonocyte proliferation rates. However, E2 treated mice did exhibit increased 
rates of apoptosis, particularly in the bottom third of the crypt with GEN trending in the 
same fashion. Thus, for the first time, these data indicate that E2 treatment and dietary 
levels of GEN can alter the physiology of normal, healthy colonic tissue by inducing 
apoptosis in a non-transformed colonocyte. This physiologic alteration may then give 
rise to the protective effects observed against colon cancer development as damaged 
cells are eliminated.  
Future Research 
Although these data are the first steps toward understanding the chemo-
protective roles of E2 and GEN in non-malignant colonocytes, further investigations 
should be initiated to determine the precise roles of these compounds in normal colonic 
tissue. Also, determining optimum concentrations of these compounds to exert beneficial 
effects should be a primary focus of researchers.  Once results are generated in a mouse 
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models that provide an estimated level of consumption at which chemoprevention is 
optimized, human trials should follow.    
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